ModifiedPremera BluecrossPolicy G2056

Diagnosis of Idiopathic Environmental Intolerance (IEI) testing

Defines coverage and non‑coverage for laboratory and other tests used to diagnose or evaluate idiopathic environmental intolerance (IEI) and related proprietary test panels for Premera Blue Cross members and ordering providers.

Policy Summary

PayerPremera Bluecross

PolicyDiagnosis of Idiopathic Environmental Intolerance (IEI) testing

Policy CodePolicy G2056

Change TypeMaterial coverage change + coding update

Effective DateFeb 6, 2026

Next Review DateN/A

Key ActionDo not submit claims for any testing intended to diagnose IEI; such tests are not reimbursable.

SourceLink

POLICY UPDATE CHANGES

New policy states that in all circumstances, any type of testing for idiopathic environmental intolerance (IEI) is not reimbursable.

Coding update removed CPT codes 83921 and 84600.

0IEI testing reimbursed

2CPT codes removed

90Provider notification period (days)

33%SIBO positivity (large series)

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not reimbursable (explicit list)

Not reimbursable indications (explicit):

Not reimbursable tests for IEI: In all circumstances, laboratory tests designed to confirm the diagnosis of idiopathic environmental intolerance (IEI) are not reimbursable.

Not reimbursable: screening for solvents/organic acids/organophosphates: Screening of blood, saliva, serum, plasma, urine, and/or stool samples for volatile solvents, organic acids, and organophosphates is not reimbursable.

Not reimbursable: phthalates and parabens profiling: Profiling of phthalates and parabens using blood, serum, plasma, saliva, urine, and/or stool samples is not reimbursable.

Not reimbursable: chlorinated pesticides in asymptomatic individuals: For asymptomatic individuals, profiling of chlorinated pesticides (including DDE and DDT) using blood, serum, plasma, saliva, urine, and/or stool samples is not reimbursable.

Not reimbursable: metabolic/nutritional panels in asymptomatic individuals: In asymptomatic individuals and/or during general encounters without abnormal findings, testing for carnitine sufficiency, oxidative stress and antioxidant sufficiency, detoxification adequacy, methylation sufficiency status, lipoic acid and CoQ10 sufficiency, and/or intestinal hyperpermeability is not reimbursable.

Not reimbursable: vitamin/mineral/nutritional analysis in asymptomatic individuals: In asymptomatic individuals and/or during general encounters without abnormal findings, testing for vitamin sufficiency, mineral sufficiency, and/or nutritional analysis is not reimbursable.

Not reimbursable: breath hydrogen/methane tests for IEI and other non-indicated uses: The use of a breath hydrogen and/or breath methane test to assess or diagnose idiopathic environmental intolerance, food allergies/sensitivities, carbohydrate sensitivity/intolerance, digestive disorders, constipation/diarrhea/flatulence, neurological/neuromuscular disorders, rosacea, obesity, or as part of a wellness visit/general encounter without abnormal findings is not reimbursable.

Not reimbursable: metals testing in asymptomatic individuals: In asymptomatic individuals and/or during general encounters without abnormal findings, testing of blood, serum, urine, cerebrospinal fluid, fingernails, hair, and/or stool samples for metals is not reimbursable.

When breath testing may be appropriate

Guideline-informed coverage considerations for breath testing and related diagnostics

Breath testing for SIBO or carbohydrate maldigestion: Consider breath testing when ALL of the following are met: (1) patient has compatible symptoms (eg, bloating, abdominal pain, gas, diarrhea, or constipation); AND (2) no alternative diagnosis is identified on endoscopy or imaging; AND (3) there are predisposing conditions or clinical context suggesting possible SIBO (eg, prior luminal abdominal surgery, suspected motility disorder).

Choose glucose or lactulose protocols per guideline; evaluate methane specifically when constipation is prominent; interpret results cautiously due to variable sensitivity and specificity.

Carbohydrate maldigestion testing

Use of breath testing for specific carbohydrate maldigestion

Carbohydrate-specific testing: Lactose breath tests can be useful for assessing lactose malabsorption but are not definitive; fructose and sorbitol breath tests lack validated gold standards and sufficient validation studies. Blind sugar challenge remains the most valid technique to demonstrate clinical carbohydrate intolerance.

Guidance: lactose and fructose breath tests should be performed for at least 3 hours per consensus; rule out SIBO before lactose/fructose testing.

Not Medically Necessary / Not Reimbursable for IEI testing

Not covered in all circumstances

IEI testing not reimbursable: Any type of testing for idiopathic environmental intolerance (IEI) is not reimbursable under the Routine Test Management policy, effective for dates of service on or after February 6, 2026.

Proprietary multi‑analyte panels and single‑analyte tests are frequently marketed to evaluate patients reporting idiopathic environmental intolerance (IEI). Examples include Genova Diagnostics panels (Organix, NutrEval FMV, GI Effects, SIBO Profile, Triad Bloodspot, ONE FMV), SpectraCell Micronutrient Test/SPECTROX, Life Extension nutrient panels, and Vibrant America nutrient panels. While some component tests may have legitimate uses in specific clinical contexts, their routine use to diagnose or confirm IEI is not supported because IEI lacks consistent, testable biological signatures and virtually any test can be ordered under the broad label of IEI.

Major professional societies and expert groups have expressed skepticism about IEI (formerly multiple chemical sensitivity) and recommend caution with nonvalidated tests. Historic statements from the American Medical Association, the American College of Physicians, the American Academy of Allergy, Asthma and Immunology, and the American College of Occupational and Environmental Medicine note the absence of consistent physical or laboratory findings for IEI and advise against routine use of unvalidated immune‑based or multi‑analyte panels for this condition.

Consistent with the policy's explicit coverage stance, any laboratory testing performed to diagnose or confirm idiopathic environmental intolerance (IEI) is not reimbursable in all circumstances. This policy-level noncoverage is effective for dates of service on or after February 6, 2026 and applies regardless of the specific proprietary panel or analyte claimed.

Because there is a lack of available published scientific literature demonstrating that laboratory tests meaningfully benefit diagnosis or treatment of IEI, the policy considers tests designed to confirm IEI as not medically necessary. The evidence base for intracellular micronutrient testing and many proprietary panels is limited and does not show clear patient‑oriented outcomes supporting their use for IEI.

Intracellular micronutrient assays and measurement of hepatic proteins (albumin, prealbumin) have been proposed for nutritional assessment, but published evidence does not support their routine use as standalone diagnostics for IEI or for defining malnutrition. The Academy of Nutrition and Dietetics and other reviews note that albumin and prealbumin are not reliable indicators of nutritional status and do not change predictably with nutrient intake; similarly, there is little robust evidence that intracellular micronutrient testing leads to improved clinical outcomes in IEI.

At the policy level, all testing to assess or diagnose idiopathic environmental intolerance (IEI) is considered not reimbursable. Claims for such testing are therefore subject to denial under this Routine Test Management policy.

Covered Indications

Symptom-directed testing unrelated to diagnosing IEI (basic labs and targeted tests)

Symptom-directed testing unrelated to diagnosing IEI (eg, basic labs, testing as indicated by history/exam for specific conditions such as suspected SIBO or lactose intolerance).

Appropriate basic/screening tests for symptomatic evaluation: Perform symptom-directed basic laboratory evaluation (eg, complete blood count, serum electrolytes and glucose, urinalysis) and further testing guided by reported symptoms and clinical exam.

Include occupational/environmental history and consider psychiatric screening as clinically indicated.

Breath testing for validated indications only: Breath hydrogen/methane testing may be appropriate when ordered for validated indications such as suspected SIBO or carbohydrate maldigestion and not for diagnosing IEI.

Document compatible symptoms and prior evaluations (eg, endoscopy/imaging) before ordering breath testing.

Symptomatic patients with GI symptoms when other causes excluded — breath testing may be appropriate

Symptomatic patients with bloating, abdominal pain, gas, diarrhea, or constipation when other causes have been excluded or when predisposing conditions for SIBO exist.

Indications for breath testing in symptomatic patients: Consider breath testing for patients with compatible gastrointestinal symptoms when there is an absence of another diagnosis on endoscopy or imaging and when predisposing conditions for SIBO exist (eg, prior abdominal surgery, suspected motility disorder).

Evaluate methane specifically when constipation is a prominent feature; breath testing is suggested by consensus guidelines but evidence quality is variable.

Explicit statement that no indications are covered due to policy noncoverage for IEI testing (reference)

Explicit statement that no indications are covered due to policy noncoverage for IEI testing

Policy-level noncoverage for IEI testing: Despite selected clinical indications for breath testing in non-IEI contexts, this policy explicitly states that any testing performed to assess or diagnose idiopathic environmental intolerance (IEI) will not be reimbursed.

Effective for dates of service on or after February 6, 2026; claims for IEI testing are at risk for denial.

Coding

Covered/Listed CPT and HCPCS Codesmixed

82108	Aluminum
82127	Amino acids; single, qualitative, each specimen
82136	Amino acids, 2 to 5 amino acids, quantitative, each specimen
82139	Amino acids, 6 or more amino acids, quantitative, each specimen
82300	Cadmium
82379	Carnitine (total and free), quantitative, each specimen
82380	Carotene
82441	Chlorinated hydrocarbons, screen
82495	Chromium
82507	Citrate

1–10 of 39

1/4

Removed/Updated CPT CodesCPT

83921	Removed per 02/06/26 coding update
84600	Removed per 02/06/26 coding update

Note

Codes listed (no PA requirement stated in excerpt) — highlight CPT 91065 among codes

Codes listed in the policy (no separate prior authorization stated). Highlight: CPT 91065 is included among listed codes relevant to breath testing.

91065

Prior Authorization

Coding update / Prior authorization note — removal of CPT codes 83921 and 84600; no PA for IEI specific

Prior authorization / regulatory note: policy history notes a coding update removing CPT 83921 and 84600 and a firm statement that any testing for idiopathic environmental intolerance (IEI) is not reimbursable. Additionally, the policy references regulatory context and disclaimers about member benefits and that the policy does not apply to Medicare Advantage.

IEI-related testing is non-reimbursable per policy
CPT 83921 and 84600 removed effective 02/06/26
Consult member benefit booklet for coverage specifics
Policy does not apply to Medicare Advantage

Provider Actions and Considerations

Documentation Required

LDTs must meet CLIA high‑complexity validation (no PA specified)

Laboratory-developed tests (LDTs) referenced in the policy are regulated under CLIA ’88 as high‑complexity tests and must be validated and performed in-house; the policy does not specify prior authorization codes.

LDTs are not FDA-approved/cleared and are regulated by CMS as high‑complexity tests under CLIA ’88.
Labs must validate and perform LDTs in-house; FDA clearance is not required for clinical use per the policy excerpt.

Step Therapy

Stepwise, symptom‑directed testing (avoid broad panels)

Use a stepwise, symptom‑directed testing approach rather than broad, nonvalidated panels — order tests guided by reported symptoms and clinical evaluation.

Clinical guidance: order testing based on reported symptoms and findings; avoid routine use of broad proprietary panels for IEI.
Consider psychiatric screening and use of questionnaires (eg, PHQ‑9, EESI) as clinically indicated.

Step Therapy

Evaluate other diagnoses first; consider breath testing for SIBO/carbohydrate maldigestion

Before ordering breath testing, evaluate and exclude alternative diagnoses (endoscopy/imaging as indicated) and consider breath testing for SIBO or carbohydrate maldigestion per guideline recommendations.

Follow guideline-recommended sequencing: evaluate for other causes and consider breath testing when symptoms persist and alternative diagnoses are excluded.
Assess methane specifically when constipation or slowed transit is present.

Note

(No text — placeholder not provided in brief).

Documentation Required

Recommended clinical evaluation components before testing

Include a detailed history, focused physical exam, basic labs (CBC, serum electrolytes and glucose, urinalysis), and occupational/environmental exposure history when evaluating for IEI or ordering related testing.

Obtain history and physical exam.
Order basic laboratory tests: CBC, serum electrolytes and glucose, urinalysis.
Document occupational/environmental exposure history and consider screening questionnaires (eg, EESI).

Documentation Required

Clinical documentation required before ordering breath testing

Document symptoms compatible with SIBO or carbohydrate maldigestion and prior evaluations (eg, endoscopy or imaging) and note suspected predisposing conditions (prior abdominal surgery, motility disorder, constipation) when ordering breath testing.

Record clinical symptoms (bloating, abdominal pain, gas, diarrhea, constipation).
Document prior evaluations that excluded other causes (endoscopy, imaging).
Document rationale for methane testing if constipation or slow transit is suspected.

Billing Rule

Member benefit verification required

Verify coverage for the individual member by consulting the member benefit booklet or contacting member services; the policy is a coverage guide and member contracts may differ.

Check member benefit booklet or contact member services to confirm coverage for specific services.
Policy effective dates and provider notification are noted but coverage depends on member contract.

Denial Risk

Examples of non‑reimbursable IEI‑related tests (denial risk)

Do not submit claims for laboratory tests intended to confirm IEI (examples: screening for volatile solvents, organic acids, organophosphates; phthalates/parabens profiling; chlorinated pesticides in asymptomatic individuals; broad micronutrient or metals testing in asymptomatic people) — such claims are not reimbursable and are at risk for denial.

Examples of non‑reimbursable tests: volatile solvents, organic acids, organophosphates, phthalates/parabens profiling, chlorinated pesticides in asymptomatic individuals.
Broad nutritional/micronutrient panels and metals testing in asymptomatic individuals are not reimbursable.

Documentation Required

LDTs for IEI are CLIA high‑complexity and require in‑house validation

Laboratory-developed tests for IEI that lack FDA clearance are regulated as high‑complexity LDTs under CLIA ’88 and must be validated and performed in-house; lack of FDA approval does not by itself preclude clinical use but has regulatory and validation implications.

LDTs are regulated by CMS as high‑complexity tests under CLIA ’88.
Labs must validate and perform these tests in‑house since they are not FDA-approved/cleared.

Denial Risk

Denial risk — all IEI testing not reimbursable

Claims for any type of testing to diagnose or assess idiopathic environmental intolerance (IEI) are not reimbursable and are subject to denial per the policy’s explicit coverage stance effective 02/06/2026.

Policy statement: In all circumstances, laboratory tests designed to confirm the diagnosis of IEI are not reimbursable.
Effective policy history: IEI testing non‑reimbursement added to Routine Test Management effective 02/06/2026.

Ordering Requirements

Prior Authorization

Ordering requirement — symptom‑guided testing and exposure history

Order tests only when guided by reported symptoms and a clinical evaluation; include occupational/environmental exposure history and consider psychiatric screening as clinically indicated.

Tests should be symptom‑directed and based on clinical evaluation.
Include occupational/environmental history and consider screening tools (eg, PHQ‑9, EESI).

Documentation Required

Ordering requirement — clinician documentation of compatible symptoms and rationale

Ensure the ordering clinician has documented compatible symptoms and prior evaluation results; document the clinical rationale for testing (eg, suspected SIBO, prior abdominal surgery, motility disorder, or need to evaluate methane).

Ordering clinician must document compatible symptoms and prior evaluations (endoscopy/imaging).
Document specific rationale such as suspected SIBO or need to assess methane in constipation.

Billing Rule

Ordering requirement — verify member benefits or contact member services

Verify member benefits or contact member services prior to ordering; the policy provides general guidance and does not specify specialty‑specific ordering privileges.

Confirm member coverage with benefit booklet or member services.
Policy is a guide; coverage depends on individual member contracts.

Definitions

Idiopathic environmental intolerance (IEI) — definition summary

Definition summaryIdiopathic environmental intolerance (IEI) is a subjective condition of recurrent, nonspecific symptoms attributed to low‑level chemical, biologic, or physical agents without consistent objective diagnostic findings or defining laboratory tests.

Former nameAlso known as multiple chemical sensitivity (MCS)

Clinical featuresSymptoms are heterogeneous (eg, anxiety, shortness of breath, chest pain, headaches) and psychiatric comorbidity is common

Diagnostic markersNo characteristic laboratory abnormalities reliably linked to IEI; objective diagnostic tests are lacking

SIBO breath test — definition

Test descriptionNoninvasive test using an oral carbohydrate substrate (glucose or lactulose) with measurement of exhaled hydrogen and/or methane to infer small intestinal bacterial overgrowth (SIBO)

Physiologic basisIn SIBO, early rises in breath hydrogen/methane occur due to metabolism by small bowel bacteria versus later colonic peaks in unaffected individuals

SubstratesCommon substrates: lactulose or glucose; choice and interpretation follow guideline recommendations

LimitationsSensitivity and specificity are variable; false positives/negatives can occur with altered transit (eg, short bowel, delayed gastric emptying)

Hepatic proteins (albumin, prealbumin) — definition and limitations

DefinitionHepatic proteins (albumin, prealbumin) are serum proteins historically used in assessing nutrition but are not reliable indicators of nutritional status or malnutrition alone.

Clinical limitationSerum albumin and prealbumin levels do not reliably change with short‑term alterations in nutrient intake and reflect morbidity/mortality rather than nutritional status

Guideline stanceNot recommended as defining diagnostic markers for protein‑energy malnutrition or sole diagnostics for malnutrition

IEI abbreviation and alternate name

AbbreviationIEI = Idiopathic environmental intolerance

Alternate nameAlso referred to as Multiple Chemical Sensitivity (MCS)

Related abbreviationsSee terminology: LDTs = Laboratory‑developed tests; SIBO = Small intestinal bacterial overgrowth

OpenPayer

Diagnosis of Idiopathic Environmental Intolerance (IEI) testing

Coverage Criteria

Covered Indications

Coding

Provider Actions and Considerations

Not Covered

Ordering Requirements

Background

Definitions

Frequency Limits

Revision History